MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.

Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion

Bumetanide vs. Furosemide in Cirrhosis

Phase 3
Not yet recruiting
Conditions
Cirrhosis
Interventions
First Posted Date
2025-04-23
Last Posted Date
2025-04-23
Lead Sponsor
Stacy Johnson
Target Recruit Count
500
Registration Number
NCT06941415
Locations
🇺🇸

University of Utah Hospital, Salt Lake City, Utah, United States

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Phase 3
Not yet recruiting
Conditions
Acute Decompensated Heart Failure
Interventions
Device: Reprieve System
First Posted Date
2025-03-27
Last Posted Date
2025-05-13
Lead Sponsor
Reprieve Cardiovascular, Inc
Target Recruit Count
400
Registration Number
NCT06898515
Locations
🇺🇸

University of California Irvine, Irvine, California, United States

🇺🇸

Trinity Health Ann Arbor Hospital, Ann Arbor, Michigan, United States

🇺🇸

St. Louis VA, St. Louis, Missouri, United States

and more 8 locations

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

First Posted Date
2025-03-27
Last Posted Date
2025-05-15
Lead Sponsor
AstraZeneca
Target Recruit Count
45
Registration Number
NCT06899061
Locations
🇷🇴

Research Site, Cluj Napoca, Romania

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts At Tertiary Care Hospital in Karachi.

Early Phase 1
Conditions
Cutaneous Warts
Interventions
First Posted Date
2025-02-12
Last Posted Date
2025-02-12
Lead Sponsor
Jinnah Postgraduate Medical Centre
Target Recruit Count
40
Registration Number
NCT06821594
Locations
🇵🇰

Jinnah Postgraduate Medical Centre, Karachi, Sindh, Pakistan

Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1

Not Applicable
Conditions
Cardiorenal Syndrome Type 1
Interventions
First Posted Date
2025-01-22
Last Posted Date
2025-01-22
Lead Sponsor
Benha University
Target Recruit Count
146
Registration Number
NCT06786728
Locations
🇪🇬

Asmaa Shahat Mohamedy Behairy, Cairo, Egypt

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-07-17
Last Posted Date
2025-03-06
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT06504862
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent

Not Applicable
Recruiting
Conditions
Healthy
Interventions
First Posted Date
2024-06-21
Last Posted Date
2025-04-01
Lead Sponsor
National Aeronautics and Space Administration (NASA)
Target Recruit Count
38
Registration Number
NCT06467825
Locations
🇺🇸

NASA, Houston, Texas, United States

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Phase 4
Not yet recruiting
Conditions
Heart Failure With Preserved Ejection Fraction
Heart Failure Acute
Diabetes Type 2
Heart Failure With Reduced Ejection Fraction
Interventions
Drug: Hypertonic Saline Solution, 1 Ml
First Posted Date
2024-06-04
Last Posted Date
2024-06-06
Lead Sponsor
University of Palermo
Target Recruit Count
544
Registration Number
NCT06442280

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

Phase 3
Not yet recruiting
Conditions
ER+ Breast Cancer
HER2-negative Breast Cancer
Breast Cancer Stage III
Breast Cancer Stage I
Drug-Related Side Effects and Adverse Reactions
Musculoskeletal Pain
Breast Cancer Stage II
Interventions
Behavioral: Booklet for healthy behaviors
First Posted Date
2024-05-09
Last Posted Date
2024-11-05
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
399
Registration Number
NCT06407401

Role of Active Deresuscitation After Resuscitation:

Phase 2
Not yet recruiting
Conditions
Fluid Overload
Critical Illness
ARDS
Trauma
Sepsis
Interventions
First Posted Date
2024-03-22
Last Posted Date
2024-03-22
Lead Sponsor
Unity Health Toronto
Target Recruit Count
120
Registration Number
NCT06326112
Locations
🇨🇦

Unity Health Toronto, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath